Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 63 EV-to-EBIT is -15.88 as of Sep. 05, 2026. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.24 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 108 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 925925% on this metric.
The historical rank and industry rank for Pangaea Oncology's EV-to-EBIT or its related term are showing as below:
XMAD:PANG'
s EV-to-EBIT Range Over the Past 10 Years
Min: -48.56 Med: -17.57 Max: -5.18
Current: -15.88
During the past 13 years, the highest EV-to-EBIT of Pangaea Oncology was -5.18. The lowest was -48.56. And the median was -17.57.
XMAD:PANG's EV-to-EBIT is ranked worse than 100% of 108
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.48
vs XMAD:PANG: -15.88
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pangaea Oncology's Enterprise Value for the quarter that ended in Dec. 2025 was €65.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology EV-to-EBIT Related Terms
Pangaea Oncology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, NTRA: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's EV-to-EBIT falls into.
Pangaea Oncology's current Enterprise Value is €59.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a EV-to-EBIT of -15.88 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #999999 out of 108 companies in the Medical Diagnostics & Research industry.
Is Pangaea Oncology's EV-to-EBIT too high?
Pangaea Oncology's current EV-to-EBIT is -15.88. Based on the distribution chart, Pangaea Oncology ranks #999999 out of 108 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #999999 out of 108 companies for EV-to-EBIT. This places Pangaea Oncology in the lower half of its industry. The industry median EV-to-EBIT is 24.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.48, based on 108 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current EV-to-EBIT is -15.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.24, compared to a current price of €1.55 — trading 30.8% below its estimated fair value. The current EV-to-EBIT is -15.88. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current EV-to-EBIT is -15.88 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 30.8% below its estimated GF Value™ of €2.24.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
EV-to-EBIT: -15.88
GF Value™: €2.24 vs. price of €1.55 (30.8% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
